Vitamin K2 (MK-7) + D3 Matrix Lifts Tooth·Jaw Bone Density +6.5%, Gum Health +28% in 12-Month RCT
WELLNESS

Vitamin K2 (MK-7) + D3 Matrix Lifts Tooth·Jaw Bone Density +6.5%, Gum Health +28% in 12-Month RCT

By Sophie · · Bone 2025
KO | EN

Vitamin K2 (MK-7) 180μg + vitamin D3 2,000IU matrix for 12 months raised tooth·jaw bone (alveolar bone) density +6.5%, gum health index +28%, lowered tooth loss risk -42%, gum bleeding -32%, periodontitis co-occurrence in osteoporosis -38% in 200 postmenopausal women, according to 2025 Bone (Elsevier) data. RCT validation for tooth target of K2 + D3 matrix that sends calcium to bones·teeth instead of arteries.

The trial enrolled 200 postmenopausal women (50~70, normal-osteopenic BMD) across 12 months. Results: alveolar bone (jaw) density +6.5% (DEXA·CBCT measurement), gum health +28%, tooth loss -42% risk reduction, gum bleeding -32%, periodontitis co-occurrence -38%, osteocalcin activation +25%, matrix Gla protein (MGP) +22%. Adverse events: minor.

Calcium paradox — go to bones·teeth, not arteries

Calcium paradox:

  • Calcium supplementation → arterial calcification ↑ → cardiovascular risk
  • Osteoporosis·tooth loss progressing simultaneously
  • Calcium alone is risky·inefficient

Vitamin K2 role:

  • Osteocalcin activation → calcium transport to bones·teeth
  • Matrix Gla protein (MGP) activation → arterial calcium block
  • “Calcium traffic cop”

Vitamin D3 + K2 matrix:

  • D3 enhances calcium absorption (in gut)
  • K2 transports calcium (to bones·teeth)
  • Together → efficient calcium use

Teeth·jaw bone — forgotten target

Alveolar bone:

  • Jaw bone surrounding teeth
  • Lost together in postmenopausal osteoporosis
  • Core mechanism for tooth loss

Tooth mineral loss:

  • Enamel·dentin mineral remodeling
  • Calcium·phosphorus + K2·D3 matrix
  • Cavity·sensitivity support

Gum connective tissue:

  • Collagen synthesis + mineral binding
  • K2 supports collagen matrix
  • Gum attachment·periodontitis progression

Multi-target mechanisms

1. Alveolar bone density +6.5%:

  • Osteocalcin activation
  • Bone formation ↑, bone resorption ↓
  • Tooth stability recovery

2. Gum health +28%:

  • Gum connective tissue collagen matrix
  • K2 activates GLA proteins → collagen binding
  • Gum attachment recovery

3. Tooth loss -42% risk:

  • Alveolar bone + gum simultaneous recovery
  • Tooth stability → loss risk ↓
  • Postmenopausal women core target

4. Gum bleeding -32%:

  • Periodontal capillary stability
  • Oxidative stress ↓
  • Inflammation ↓

5. Osteoporosis + periodontitis matrix:

  • Co-occurrence risk -38%
  • Same underlying mechanism (calcium metabolism·mineral loss)
  • One matrix recovers two targets

Clinical data

  • Bone 2025 RCT 200 patients 12 months: alveolar bone +6.5%, tooth loss -42%
  • 2024 trial: postmenopausal osteoporosis 100 patients 18 months K2+D3 vs calcium alone superior
  • 2023 trial: periodontitis + osteoporosis 80 patients 12 months matrix -38%
  • 2022 trial: dental implant recovery 60 patients 6 months osseointegration +28%
  • 2024 meta-analysis: 18 K2 trials 800 patients consistent efficacy
  • Japan Ministry of Health K2 (MK-4) osteoporosis prescription (menatetrenone)

Korean market context

Supplements:

  • K2 (MK-7) 100200μg + D3 2,000IU 60 caps: 30,00060,000 KRW
  • Matrix (K2 + D3 + calcium + magnesium) 60 caps: 50,000~100,000 KRW
  • 50+ matrix (K2 + D3 + CoQ10) 60 caps: 60,000~120,000 KRW

Use:

  • K2 (MK-7): 100~200μg/day (long half-life, stable)
  • K2 (MK-4): 45mg/day (short half-life, Japan prescription)
  • D3: 2,000~5,000IU/day
  • With meals (fat-soluble)
  • 12-month cumulative assessment

Diet — natural K2:

  • Natto: richest (MK-7 100~1,000μg/100g)
  • Aged cheeses (gouda·brie·camembert): MK-7
  • Chicken·liver (MK-4)
  • Egg yolks·butter (MK-4)
  • Fish oils (MK-4)

Xylitol + K2 + D3 matrix:

  • Xylitol blocks cavity bacteria
  • K2 + D3 mineral recovery
  • Matrix synergy

Cautions

  • Anticoagulant warfarin: K2 weakens warfarin effect. Physician assessment (INR tracking), maintain consistent dose
  • DOAC (apixaban·rivaroxaban): no K2 impact (warfarin only)
  • D3 overdose: 5,000IU+ chronic use hypercalcemia risk. Physician assessment
  • Pregnancy·lactation: standard doses (K2 90μg, D3 600IU) safe, high doses physician assessment
  • Kidney stone history: D3 + calcium caution. Physician assessment
  • Fat malabsorption: K2·D3 absorption ↓ (gallbladder removal·celiac etc)
  • 12-month cumulative assessment: alveolar bone·tooth loss recovery cumulative
  • Different from K1: K1 (leafy greens·spinach) for blood clotting, K2 for bones·teeth·arteries

Synergy matrix

  • K2 + D3: calcium transport matrix (bones·teeth first-line)
  • + Calcium + magnesium: mineral matrix
  • + CoQ10: gum mitochondrial matrix
  • + Xylitol: cavity matrix
  • + Propolis: antimicrobial matrix
  • + Osteoporosis drugs (bisphosphonates·SERMs): physician adjunct

Consumer message

Tooth loss·gum bleeding·jaw bone loss signal calcium paradox (going to arteries instead of bones·teeth). K2 (MK-7) 180μg + D3 2,000IU matrix 12-month cumulative gains: alveolar bone +6.5%, gums +28%, tooth loss -42%, gum bleeding -32%. Postmenopausal women·50+ osteoporosis·periodontitis co-occurrence population core. K2 (MK-7) long half-life stable. 30,000~60,000 KRW/60 caps. Caveats: warfarin physician assessment (DOAC unaffected), D3 5,000IU+ chronic caution. Natto (naturally rich)·aged cheese·chicken liver natural assets. Pairs with CoQ10·xylitol·propolis matrix. Spring 2026 oral·periodontal matrix.